News und Analysen
Humana Announces New Veteran Hiring Strategy and Recognition as Top Veteran-Friendly Company
Humana Inc. (NYSE: HUM), a leading health and well-being company, launches a refreshed military-connected hiring strategy and earns recognition by U.S. Veterans Magazine as a Top Veteran-Friendly
Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age
Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced top-line results from their Phase 3 clinical trial to evaluate the companies’ combined mRNA vaccine
Agilent Announces Innovative J&W 5Q GC/MS Columns for Superior Gas Chromatograph Performance
Agilent Technologies Inc., (NYSE: A) today announced the release of its new Agilent J&W 5Q GC/MS Columns, representing a major advance in gas chromatography/mass spectrometry (GC/MS) column
Pfizer Announces Top-Line Results of ABRYSVO® for RSV in Immunocompromised Adults
Pfizer Inc. (NYSE: PFE) today announced positive top-line safety and immunogenicity results from substudy B of the ongoing pivotal Phase 3 clinical trial (NCT05842967) MONeT (RSV IMmunizatiON Study
The Trust for the National Mall and Humana Announce New Programming and Advance Court Reservation Sign-up Date for National Mall of Pickleball 2024
In honor of National Pickleball Day, The Trust for the National Mall and Humana (NYSE: HUM) announce exciting program details for the three-day monumental event, National Mall of Pickleball
Agilent Receives FDA Approval for MAGE-A4 IHC 1F9 pharmDx as a Diagnostic Tool for Use with Newly Approved TCR T-Cell Therapy
Agilent Technologies Inc., (NYSE: A) today announced that it has received FDA approval for the use of MAGE-A4 IHC 1F9 pharmDx (SK032) as a diagnostic tool to aid in identifying patients with
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
QuidelOrtho Reports Second Quarter 2024 Financial Results
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs, and
Pfizer Reports Strong Second-Quarter 2024 Results And Raises 2024 Guidance
Pfizer Inc. (NYSE: PFE) reported financial results for the second quarter of 2024 and raised its full-year 2024 guidance(1) for both Revenues and Adjusted(2) diluted EPS.
The second-quarter 2024
Agilent Acquires Sigsense, Creator of AI-Enabled Lab Operations Technology
Agilent Technologies Inc. (NYSE: A) today announced it has acquired Sigsense Technologies, a San Francisco, California-based startup that uses artificial intelligence and power monitoring to help
Dexcom Reports Second Quarter 2024 Financial Results, Updates Guidance, and Announces $750 Million Share Repurchase Program
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2024.
Second Quarter 2024 Financial Highlights:
-
Revenue grew 15% year-over-year to
European Commission Approves Pfizer’s DURVEQTIX® (fidanacogene elaparvovec), a One-Time Gene Therapy for Adults with Hemophilia B
Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has granted conditional marketing authorization for DURVEQTIX® (fidanacogene elaparvovec), a gene therapy for the treatment
Humana and Google Expand Partnership to Help Reduce Cost of Care and Improve Member Experiences
Humana Inc. (NYSE: HUM), a leading health and well-being company, today announced a new multi-year agreement with Google Cloud to further modernize Humana’s cloud infrastructure and leverage
Lonza Nominates Juan Andres and Eric Drapé as Independent Board Members
Lonza Group H1 2024 Performance Well On Track to Deliver Full-Year Outlook: Sales Up 1.8% CER and 29.2% CORE EBITDA Margin
Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix
Edwards Lifesciences (NYSE: EW) today announced investments that reflect the company’s deep commitment to advancing patient care through structural heart innovation, addressing large unmet patient
Edwards Lifesciences Reports Second Quarter Results
Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2024.
Highlights and Outlook
-
Q2 sales grew 7%; constant currency1 sales grew 8%
-
Q2 TAVR
CenterWell Announces Plans to Open 23 Senior Primary Care Centers at Walmart Locations in Florida, Georgia, Missouri and Texas
CenterWell, the health care services business of Humana Inc. (NYSE: HUM), today announced plans to lease clinical space and open senior-focused primary care centers at 23 Walmart Supercenter retail
Pfizer Announces Positive Topline Results From Phase 3 Study of Hemophilia A Gene Therapy Candidate
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 AFFINE study (NCT04370054) evaluating giroctocogene fitelparvovec, an investigational gene therapy for the
Sartorius Stedim Biotech SA: Information on Document Availability
Sartorius Stedim Biotech SA: Sartorius Stedim Biotech adjusts its guidance for fiscal year 2024 and presents results for H1 2024
Humana Accelerates Commitment to Helping Seniors Choose Right Health Plan, Announces Minority Investment in Healthpilot
Leading health and well-being company Humana Inc. (NYSE: HUM), through its payor-agnostic insurance brokerage business, today announced a minority investment in Healthpilot, a company pioneering
QuidelOrtho to Report Second Quarter 2024 Financial Results
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and
Edwards Lifesciences to Host Earnings Conference Call on July 24, 2024
Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended June 30, 2024 after the market closes on Wednesday, July 24, 2024, and will host a conference call at